INTRODUCTION
Tumor-associated antigens (TAAs) have been shown to induce specific T cell immune-responses in tumor patients, and thus represent potential target structures for specific immunotherapies [1] [2] [3] [4] . Recently, a large number of TAAs inducing specific T cell responses has been identified and functionally characterized in different solid tumors, but several TAAs also seem to be expressed in hematological malignancies like acute myeloid leukemia (AML)
[http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm] 5 .
AML is the most common acute leukemia in adults. With intensive induction therapy complete remission (CR) rates between 65% and 75% are achieved in younger patients (< 60 years). However, more than 50% of these patients will relapse, leading to an overall survival rate of only 30% to 40% after five years. Results are more unfavorable in patients older than 60 years 6, 7 . Immunotherapeutic approaches targeting TAAs to prevent relapse may represent a promising novel treatment option to improve the outcome of AML patients.
Recently, in AML patients specific T cell responses of cytotoxic T-lymphocytes (CTLs)
were detected against the Wilms Tumor gene WT1, Proteinase 3 (PRTN3) and the receptor for hyaluronic acid mediated motility RHAMM (also known as CD168 or HMMR) [8] [9] [10] [11] [12] [13] [14] . For these TAAs clinical peptide vaccination trials have been initiated including AML patients 8, 15, 16 . Furthermore, additional TAAs known to induce specific immune responses of CD8+ T cells like PRAME, G250/CA9, BCL2, LAMR1 and hTERT are also frequently expressed in AML [17] [18] [19] [20] .
While immunotherapy eliciting a specific T-cell response to TAAs expressed by leukemic blasts constitutes an interesting option to enhance specific anti-leukemic effects following chemotherapy or stem cell transplantation, the clinical relevance of TAA expression in the course of AML is largely unknown. The expression of certain TAAs might play an important role in the anti-leukemic activity of the patient's immune system having achieved a complete remission by killing residual tumor cells named minimal residual disease. Therefore, expression of TAAs might be associated with outcome of AML patients.
only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From 4 Today, novel approaches in genomics like DNA microarray technology have made feasible the simultaneous measurement of thousands of transcripts in a given sample, thereby opening new potential avenues for deciphering transcriptional deregulation in tumorgenesis. Microarray technology has already contributed significantly to our understanding of hematologic malignancies [21] [22] [23] , in particular providing new insights in the molecular pathology of AML [24] [25] [26] . In addition, the generated wealth of data provides opportunities for explorative data mining, and for substantiating hypothesis-driven leukemia research.
In the present study, we investigated the influence of the expression levels of leukemia relevant TAAs on the clinical outcome of AML patients by re-analyzing a previously published large gene expression data set 24 . Interestingly, high expression of TAAs G250/CA9, RHAMM/HMMR and PRAME, which we found to be associated with favorable clinical outcome in AML patients, also induced strong T cell responses, and therefore represent promising new targets for future monovalent or polyvalent immunotherapeutic approaches.
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MATERIALS AND METHODS

Samples
Peripheral blood and bone marrow samples from adult AML patients were provided by the German-Austrian AML Study Group (AMLSG) with patient informed consent and institutional review board approval from all participating centers. Approval was obtained from the University of Ulm's institutional review board for the reported studies. For cDNA microarray analysis peripheral blood (n=53) and bone marrow samples (n=63) were collected at the time of diagnosis as previously described 24 . For functional experiments, peripheral blood samples were collected from AML patients in complete remission (CR) (n=20) and AML patients with refractory disease (n=10). For the antigens G250/CA9 and PRAME 10 AML patient samples were tested, and for the antigen RHAMM/HMMR 20 AML samples were examined in complete remission, 10 in addition to the previously reported cases 8 . Furthermore, for all the three antigens 10 samples of AML patients with refractory disease were analyzed. Peripheral blood sample controls were obtained from 10 healthy volunteers.
Sample preparation
Mononuclear cells (MNCs) were prepared by Ficoll density gradient centrifugation and stored at -80 °C for RNA-preparation. For the cellular assays Ficoll-separated MNCs were resuspended with fetal calf serum (FCS) containing 10% DMSO, stored in liquid nitrogen, and thawed for immunological analyses.
Culture of cell lines
The human cell lines K-562, HL-60, KASUMI-1, KG-1, OCI-AML5 and COS-7 were obtained from the DSZM in Braunschweig, Germany. Cell lines were cultured under standard conditions in RPMI 1640 (Biochrom, Berlin, Germany) containing 10 % FCS, 2 mM L-glutamine, 100 units/ml penicillin and 100 units/ml streptomycin. 
cDNA microarray based gene expression analysis
To investigate the expression levels of relevant TAAs in adult AML we analyzed a large cDNA microarray based gene expression data set which was previously published 24 and is publicly available in the Gene Expression Omnibus database (accession number GSE425). Updated clinical follow up data is available as Supplementary Table 1 .
Fluorescence ratios of well-measured spots were normalized by mean-centering each gene across all arrays within each of three array print runs, to minimize potential print runspecific bias 24 . For hierarchical clustering, we applied two-way, average linkage hierarchical clustering 27 
Real-time RT-PCR
The mRNA expression of RHAMM/HMMR and G250/CA9 was also quantified by realtime RT-PCR using the light cycler SYBR Green I technology according to the manufacturer's protocol 18 . Expression analysis of RHAMM/HMMR and PRAME was performed as previously described 8, 18 . Real-time RT-PCR of G250/CA9 expression was performed using the primers of our conventional G250/CA9 PCR 1 approach (see above)
with an initial denaturation at 95°C for 10 min, following 40 
Peptides used for cellular experiments
To show specific T cell responses against the antigen RHAMM/HMMR we used the RHAMM/HMMR-derived R3 peptide (ILSLELMKL) in all experiments as described previously 8 . For the evaluation of specific T cell responses against PRAME we tested four PRAME-specific peptides in healthy volunteers. In AML patients we then used the PRAME-derived P3 peptide (ALYVDSLFFL) and PRAME-derived P1 peptide 
Mixed lymphocyte peptide culture (MLPC)
MNC from AML patients and healthy volunteers were selected by magnetic beads through a MACS column (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). CD8 negative antigen presenting cells (APC) were irradiated with 30 Gy and pulsed for 2 h with either a TAA derived peptide or a control peptide at a concentration of 10 µg/ml. For all RHAMM/HMMR, G250/CA9, and PRAME peptides as well as for the control peptides the same conditions and reagents were used as described previously 8 . Results from patients in complete remission were compared to results detected in samples from AML patients with refractory disease.
IFN-γ/Granzyme B ELISPOT assays
IFN-γ and granzyme B ELISPOT assays were performed according to the manufacturer's instructions as previously described 
RESULTS
Expression of TAAs in adult AML
To investigate the expression of TAAs in adult AML, we first re-analyzed our previously published cDNA microarray based gene-expression data set 24 . Interestingly, all investigated genes considered to code for relevant TAAs in AML (TERT, WT1, PRTN3, BCL2, LAMR1, PRAME, RHAMM/HMMR, and G250/CA9) exhibited highly-variable expression (i.e. ≥ 4-fold from the mean in at least two samples) in our large sample set 24 encompassing the major cytogenetic AML subgroups (data not shown). As some of the analyzed genes, including G250/CA9, showed low expression levels and had been filtered out in our previous data analysis 24 , we performed both conventional and quantitative real-time RT-PCR to confirm our microarray findings for a set of TAAs:
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Correlation with clinical findings
Correlations of our gene expression data with clinical [age, white blood cell (WBC) counts, blast counts, serum lactate dehydrogenase (LDH) levels, history of a preceding malignancy], cytogenetic (karyotype) and molecular-genetic findings (FLT3 and MLL aberrations 29, 30 ) are summarized in Table 1 . In brief, for TERT and BCL2 we did not find any significant correlation with important clinical characteristics. Higher levels of RHAMM/HMMR and LAMR1 were associated with WBC counts < 30 G/l (P=0.027 and P=0.002, respectively; Student's t-test), while lower levels of LAMR1 and PRAME were correlated with a history of preceding malignancy (P=0.047 and P=0.020, respectively; Student's t-test). We also observed a significant association of PRAME, PRTN3, LAMR1
and G250/CA9 levels with distinct karyotypes (P<0.001, P=<0.001, P=0.044 and P=0.004, respectively; ANOVA). Cases with a t(8;21), del(7q)/-7 and t(15;17) showed higher levels of PRAME, while cases with complex karyotypes or inv(16) exhibited lower means of PRAME. t(8;21) and inv(16) were associated with higher relative levels of PRTN3, and t(9;11) and del(7q)/-7 with lower levels. On the other hand, for LAMR1 there was a correlation of del(7q)/-7 with higher expression. Interestingly, in G250/CA9, del(7q)/-7 was also associated with higher mRNA levels as were cases with t(9;11), while complex karyotypes and t(15;17) showed a correlation with lower mean G250/CA9 levels.
Regarding well-known molecular markers, we only found a significant correlation of higher WT1 levels with FLT3 ITD (internal tandem duplications) (P=0.046; Student's t-test).
Correlation with outcome
Correlating our findings with outcome data, we observed a statistically significant association of higher G250/CA9 expression with favorable overall survival (P=0.022, log rank test; expression values were dichotomized by the median; Figure 1a ). Interestingly, in PRAME and RHAMM/HMMR, two additional genes coding for TAAs known to produce potent immune responses 8, 19 , we discovered similar effects. For PRAME we saw a trend towards longer overall survival in cases with higher PRAME expression (P=0.103; log only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From rank test), and the Kaplan-Meier plot for RHAMM/HMMR was suggestive for a similar effect (P=0.284) (Figures 1b and c) . For PRTN3 and WT1 the correlation of expression levels and clinical outcome has been controversially discussed recently 31, 32 . Our data did not show a correlation with clinical outcome (Figures 1d and e) . While there was also no correlation of TERT or LAMR1 expression levels with outcome (Figures 1f and g ), higher BCL2 levels suggested poorer overall survival although not statistically significantly (P=0.250; log rank test; Figure 1h ).
These observations denoted that the expression of certain tumor-specific TAAs was associated with a better outcome following intensive chemotherapy, possibly secondary to yet unknown immunological mechanisms. Based on this hypothesis we were interested to determine whether the expression of at least one of the three TAAs whose higher expression correlated with or showed a trend towards better outcome (Figures 1a-c) had an additive influence with regard to improved survival in AML. Thus, we assigned our samples to groups depending on whether they exhibited expression levels of RHAMM/HMMR, PRAME and G250/CA9 above the median for 0, 1, 2, or all 3 of these TAAs. Interestingly, we observed a statistically significant difference between cases showing "no" TAA expression (count = 0) and the group expressing at least one of the three TAAs (count ≥ 1), which displayed significantly longer overall survival times (P=0.005, log rank test; Figure 2 ). These TAA defined groups (no vs. ≥ 1 TAA) were independent of WBC, LDH, a history of secondary AML, cytogenetics and molecular markers, but there was a significant association between age > 60 years and "no TAA" expression (P<0.001, Chi-square test; Table 1 ). Similarly, in multivariate proportional hazards analysis higher expression levels of at least one of the 3 TAAs provided significant prognostic information independent of cytogenetics (hazards ratio 0.546, confidence interval 0.251 -0.841, P=0.04). However, in agreement with the univariate analyses the observed survival benefit was not independent of patient age. Thereby, our findings support our aforementioned hypothesis, which would also predict stronger specific immune responses in cases with higher TAA expression.
Therefore, in a next step we aimed to perform functional analyses to validate our hypothesis.
Specific cellular immune responses to RHAMM/HMMR-, PRAME and G250/CA9-derived peptides
To characterize the induction of specific T cell responses in healthy volunteers and AML patients we tested the RHAMM/HMMR-derived peptide R3, the PRAME-derived peptides P1 and P3, and the G250/CA9-derived peptides G1 and G2 (Table 2) . ELISPOT assays for pre-sensitized CD8 positive T cells from the peripheral blood were performed for the release of IFN-γ and Granzyme B after the presentation of the test peptide presented by T2 cells as described 8 . Figure 3 shows representative results for a IFN-γ (Figure 3a) and Granzyme B (Figure   3b ) release by CD8+ T cells collected from an AML patient in complete remission, who expressed RHAMM/HMMR, G250/CA9 and PRAME in the leukemic blasts at the time of diagnosis (analyzed by cDNA microarray technology and conventional RT-PCR; Figure   3c ). According to the measured gene expression levels, high numbers of reactive CD8+ T cells were counted after stimulation with the RHAMM/HMMR-derived peptides R3 and the G250/CA9-derived peptide G2. Lower numbers of spots were detectable for the PRAMEderived peptide P3. In addition, a high Granzyme B release was detected using the IMP peptide as positive control. As expected, no T cell reaction was found for the negative control (mere T2 cells without peptide). For the induction of specific T cell responses against the PRAME-derived peptides we examined samples from 10 AML patients. Positive results in ELISPOT analyses for IFN-γ only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From and Granzyme B were observed in 7/10 (70%) cases analyzed for the peptide P3 and in 1/7 (14 %) for the peptide P1, respectively. Figure 4 displays the results of an ELISPOT analysis for IFN-γ and Granzyme B for the PRAME-derived peptides P1 and P3 in an AML patient. While we were able to observe specific T cell responses against the PRAME peptide P3, none were detected against the other PRAME peptide P1 or against the negative control. Cross reactivity against an irrelevant peptide (MAGE3) was excluded.
High IFN-γ and Granzyme B release was detected for the IMP peptide serving as a positive control.
Interestingly, 6/10 (60%) of analyzed AML cases exhibited specific T cell responses against the newly characterized G250/CA9-derived peptide G2. In contrast, only 1/8 (12.5%) showed positive results for the peptide G1. In all tested samples, similar results were observed for the ELISPOT assays for IFN-γ and for Granzyme B.
We also compared the results of cellular assays from patients in complete remission to patients with refractory AML. In the latter group, no specific T cell responses were detected against the RHAMM/HMMR-derived peptide R3 (0/10) and the G250/CA9-derived peptide G2 (0/10). Specific responses of CD8+ T cells against PRAME-derived peptide P3 were found in only 40% (4/10) of refractory AML patients (Table 2) Table 3 ).
Specific cell lysis of RHAMM/HMMR-R3, PRAME-P3 and G250/CA9-G2 pulsed T2 cells
We previously described a strong specific lysis of RHAMM/HMMR-R3-pulsed/expressing cells 8 . Therefore, we wanted to demonstrate that in addition to RHAMM/HMMR-R3-, both PRAME-P3-and G250/CA9-G2-pulsed T2 cells can also be lyzed by CD8+ T cells of AML patients. Interestingly, using CD8+ T cells of AML patients we were able to show specific lysis of peptide-pulsed T2 cells of RHAMM/HMMR-R3-pulsed, of PRAME-P3-pulsed and of G250/CA9-G2-pulsed T2 cells (Figure 5a-c) .
To determine whether the specific lysis of G250/CA9-G2-pulsed T2 cells were dependent on HLA-ABC molecules, we performed HLA-ABC-blocking experiments. As earlier described for RHAMM/HMMR-R3 8 , when blocking HLA-ABC molecules we could not detect a lysis reaction using G250/CA9-G2-primed T cells (Figure 5c ). In addition, presensitized CD8+ T cells did not lyse K-562, which lacks HLA-A2 expression, but shows expression of RHAMM/HMMR, PRAME and G250/CA9 (Figure 5a-c) .
Dose-dependent cellular immune responses to RHAMM/HMMR-, PRAME and G250/CA9-derived peptides
The T cell reaction to the RHAMM/HMMR-derived peptide R3, the PRAME-derived peptide P3 and the G250/CA9-derived peptide G2 was demonstrated to be dependent on peptide concentration. Using different peptide concentrations we applied ELISPOT assays for Granzyme B and IFN -γ to indicate peptide-specific T cell responses. Based on this approach we were able to define an optimal dose of 10 µg peptide/ml which was used in consecutive assays. Figure 6 shows a representative dose-dependent reaction against the G250/CA9-derived peptide G2. Similar results were found for PRAME (data not shown). For RHAMM/HMMR dose-dependent results have been already We focused our analysis on the investigation of the expression levels of TAAs that have been shown both to exhibit the potency to induce specific immune responses in tumors and to be expressed in AML blasts. Therefore, we evaluated the expression of TERT, WT1, PRTN3, BCL2, LAMR1, PRAME, RHAMM/HMMR, and G250/CA9 8, 10, 11, [17] [18] [19] [20] .
We also validated the DNA microarray-based gene expression data by conventional and quantitative RT-PCR.
Correlation of TAA expression levels with clinical outcome showed that higher levels of TAAs known to be almost exclusively expressed in malignant tissues were positively associated with longer overall survival times. Interestingly, patients whose leukemic cells expressed at least one of the TAAs G250/CA9, PRAME or RHAMM/HMMR had a better clinical outcome than those showing low expression of all three TAAs (P=0.005, log rank test). This finding suggests that in AML the expression of distinct tumor-specific TAAs on leukemic blasts might enable the immune system to better eradicate minimal residual disease following intensive chemotherapy, thereby leading to decreased relapse rates and longer overall survival times. Why an association with longer survival was not observed with the other TAAs (TERT, WT1, PRTN3, and LAMR1) might reflect that different TAAs show different potencies to induce specific T cell responses and/or that some TAAs are not exclusively expressed on the leukemic blasts. On the other hand, an inverse correlation of survival with BCL2 expression has been previously reported [33] [34] [35] and might be ascribed to its anti-apoptotic function, an effect that might outweigh a potential immunological benefit.
Interestingly, there was a significant association between older age and "no TAA" expression. As older age is known to be associated with adverse outcome, it might be argued that the examined TAAs merely represent surrogate markers for age. However, none of the markers alone showed a significant association with age, and it is a remarkable observation that in general leukemic blasts from older patients seem to express less TAAs. This finding might be one explanation for the poorer outcome in these cases.
Further supporting our findings, expression of PRAME has been shown as an indicator of a good prognosis in childhood AML 36 , although this effect might have been secondary to its correlation with favorable cytogenetics such as a translocation t(8;21), which already has been previously described 37 . G250/CA9 is expressed in most clear cell forms of renal cell carcinoma (RCC), but not in normal tissues. In accordance with our data in AML patients, the expression of G250/CA9 has also been shown to be associated with a favorable outcome in RCC [38] [39] [40] . While some studies have shown a poor clinical outcome of AML patients expressing WT1 in the leukemic blasts 31, 41 , others described no correlation of WT1 expression with the clinical outcome 32, 42 , which is in agreement with our findings.
For RHAMM/HMMR our results are contrary to the data reported in the literature. In breast cancer and multiple myeloma RHAMM/HMMR expression was found in highly proliferating tumor cells, and there was also an association with the potential to metastasize and with worse clinical outcome 43, 44 . The connection between increased RHAMM/HMMR levels and poor outcome in these studies might reflect different underlying tumor biology, e.g. an impaired lymphatic system in multiple myeloma which might affect a possible immunological effect of TAA expression. In AML, RHAMM/HMMR is expressed in 70% of cases, whereas no expression has been detected in normal CD34-positive hematopoietic stem cells or in normal tissues (except for testis, placenta and thymus) 18 rendering it a potent immunological target for the immune system to fight a residual tumor load following chemotherapy in AML. Therefore, RHAMM/HMMR, as well as PRTN3 and WT1, is currently used in peptide vaccination trials for patients with hematological malignancies 8, 9, 16 , and effective immune responses have been demonstrated.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From To further investigate whether the observed positive clinical effects might result from the induction of specific immune responses, we analyzed the induction of specific T cell responses by G250/CA9, RHAMM/HMMR and PRAME. For RHAMM/HMMR and PRAME, HLA-A*0201-restricted immune responses and specific cell lysis of tumor cells have already been described in small AML studies 8, 19, 45 , and an epitope peptide derived from G250/CA9 recognized by specific CD8+ T cells has been described in patients with renal cell carcinoma 28 . Here, we reported the induction of specific T cell responses against the TAA RHAMM/HMMR in a larger cohort of AML patient samples with specific responses in 47% of cases. Moreover, we found specific immune responses against the PRAME-derived peptide P3 in 70 % and against the newly characterized G250/CA9-derived peptide G2 in 60 % of AML patients, thereby demonstrating a high frequency of specific T cell responses against these three TAAs in AML patients. Consistent with an impact on clinical outcome, specific T cell responses were significantly higher in AML patients in complete remission compared to those with refractory disease.
Specific immune responses were found in ELISPOT analysis for interferon gamma and Granzyme B, and these could be also confirmed by specific lysis of pulsed T2-cells in Cr-51 release assays. Furthermore, dilution series showed a specific dose-dependent T cell response against these peptides which is in concordance with our clinical observations suggesting an immunological effect based on TAA expression levels. In accordance, we also could demonstrate simultaneous CD8+ T cell responses against the peptides RHAMM/HMMR-R3, PRAME-P3 and G250/CA9-G2 in individual AML patient samples. In the future, the ability to generate these simultaneous immune responses might be helpful to overcome immunological tumor-escape mechanisms and to enhance clinical effects of vaccination against tumor cells expressing these TAAs.
In conclusion, our findings are highly suggestive that the expression of some TAAs might play a critical role in immunologic mechanisms preventing a relapse of AML. Thus, TAAs like RHAMM/HMMR, PRAME and G250/CA9 represent promising targets for future vaccination trials to further augment immune responses. Based on the observed immune responses and the favorable expression pattern of RHAMM/HMMR in normal tissues, a peptide vaccination trial for patients with hematological malignancies expressing RHAMM/HMMR is ongoing 8, 9, 16 . Furthermore, the findings of this study suggest that a only.
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